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Sudden arrhythmic death syndrome (SADS), where death is secondary to cardiac 
arrhythmia, is associated with several cardiac ion channelopathies, including long QT 
syndrome and Brugada syndrome, as well as cardiomyopathies such as hypertrophic 
cardiomyopathy and dilated cardiomyopathy.  Many of these conditions often present in 
childhood or adolescence.  This study investigates how diagnoses of cardiac diseases 
associated with SADS are communicated within families.  A questionnaire was 
distributed through cardiac disease-focused support groups and organizations.  Data from 
114 parents who have a child with a SADS condition were used for analysis. Based on 
the responses, parents explained the risk of SADS in a straightforward manner and 
related the risk to the importance of compliance with the prescribed treatment.  
Participants also found it difficult to determine and enforce lifestyle modifications, 
manage the families’ emotional reactions, convey the seriousness of the information 
without scaring their children, and discuss the risk of SADS during these conversations.  
Concerns regarding disease progression, length and quality of life, and treatment failures 
and complications were also expressed.   Healthcare providers, the Internet, other 
affected people, visual aids, and personal experience were all reported to be helpful for 
discussing the SADS condition with their children.  Services and resources that were 
requested were children’s support groups, a counselor or psychologist, and 
  v
child-oriented materials.  Increased understanding of how families discuss children’s 
diagnosis of SADS conditions will equip healthcare providers with the information to 
address parental concerns and help facilitate discussion of the condition between parents 
and their children. 
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Chapter 1: Background  
1.1 Overview of Cardiac Conditions 
Sudden cardiac death (SCD) accounts for 50-100 deaths per 100,000 in North America 
and Europe every year (McGorrian et al., 2013).  Sudden arrhythmic death is a specific 
type of SCD where sudden death is secondary to a cardiac arrhythmia.  In cases of SCD 
where a structural heart defect cannot be found, the cause of death in these individuals is 
attributed to sudden arrhythmic death syndrome (SADS) (Vyas & Lambiase, 2013).  
Several studies have investigated the incidence of SADS; it has been reported to account 
for 0.16-0.24 deaths for every 100,000 people per year. However, the prevalence of 
SADS was found to be several times higher in younger populations; it is estimated to be 
0.76 per 100,000 people per year in individuals aged 14-35 (McGorrian et al., 2013; Vyas 
& Lambiase, 2013).   
A genetic predisposition can cause an increased risk for SADS in certain family 
members. Inherited cardiac disease has been found in up to 50% of families with a 
history of SADS (Vyas & Lambiase, 2013). Several diseases affect the electrophysiology 
of the heart without altering the actual cardiac structure.  These conditions are 
collectively known as ion channelopathies and are associated with a risk of SADS.  The 
most common are long QT syndrome (LQTS), Brugada syndrome (BrS), and 
catecholaminergic polymorphic ventricular tachycardia (CPVT), but others such as 
progressive cardiac conduction defect (PCCD), early repolarization syndrome, and short 
QT syndrome are also associated with a risk of SADS (Behr, 2010; Vyas & Lambiase, 
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2013). It is thought that these conditions are responsible for about 40% of all SADS cases 
(Behr, 2010).  In about 10-20% of SADS cases, certain types of structural heart disease 
are found to be responsible. Hypertrophic cardiomyopathy (HCM), arrhythmogenic right 
ventricular cardiomyopathy (ARVC), and dilated cardiomyopathy (DCM) are the some 
of the most frequent structural heart diseases that cause SADS (Behr, 2010).  
Long QT syndrome (LQTS) is the most common ion channelopathy with a 
reported incidence ranging from 1 in 2,000 to 2,500 (Ackerman et al., 2011; Vyas & 
Lambiase 2013).  It is characterized by a prolonged ventricular repolarization and a 
predisposition for a specific type of arrhythmia known as torsades de pointes (TdP), 
which leads to syncope, seizures, and SCD; this arrhythmia can begin as early as infancy.  
However, not everyone who has LQTS will become symptomatic in their lifetime.  While 
it is not possible to predict a patient’s prognosis, the probability of developing cardiac 
symptoms is partially dependent on a person’s age, sex, and the length of the QTc 
interval.  Within the symptomatic and untreated population, the mortality rate is about 
50% (Ackerman et al., 2011).   
Congenital LQTS is also marked by locus and allelic heterogeneity.  Loss-of-
function mutations in KCNQ1 and KCNH2, which code for subunits of a cardiac 
potassium channel, are responsible for LTQ1 and LTQ2, respectively.  LTQ3 is caused 
by gain of function mutations in SCN5A, which codes for a subunit in a cardiac sodium 
channel.  Mutations in these three genes account for 70-75% of LQTS cases and are 
inherited in an autosomal dominant manner with a 5-10% de novo rate. (Ackerman et al., 
2011; Bastiaenen & Behr, 2011). The other 25% of cases are due to a variety of 
mutations in nine other known genes as well as an unknown number of unidentified 
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genes. In addition, the other 25% of LQTS may be polygenic, and can display both 
autosomal dominant and autosomal recessive inheritance (Bastiaenen & Behr, 2011).  
Management of LQTS mainly consists of pharmacotherapy with beta-blockers, 
life-style modifications, such as exercise restrictions, and avoidance of QT-prolonging 
drugs to reduce the risk of arrhythmia and syncope. High-risk patients may also have an 
ICD or pacemaker implanted (Ackerman et al., 2011).  As genotype-phenotype 
correlations have emerged, medical management for LTQ1-3 has become partially 
dependent on the specific mutation discovered in each patient.  Medical management 
with beta-blockers works best in patients with LQT1 and LTQ2; it is considered 
significantly less effective in LQT3 patients.  The triggers that are most likely to cause 
patients to become symptomatic are also gene-specific.  Exercise is a known risk factor 
for LTQ1; therefore, it is advised that these patients avoid competitive sports.  Symptoms 
for patients with LQT2 can be caused by intense emotions and startling noises.  In 
contrast, most patients with LQT3 become symptomatic while resting or sleeping 
(Napolitano, Bloise, Monteforte, & Priori, 2012).  While these genotype-phenotype 
correlations have helped with symptom management, patients may experience symptoms 
more commonly associated with a different subtype of LQTS.  Therefore, it is important 
to discuss all risk factors and possible symptoms with patients diagnosed with LQTS.   
Brugada syndrome (BrS) is characterized by a conduction delay in the right 
ventricle as well as an elevated ST segment in the right precordial leads on an 
electrocardiogram (EKG) (Bastiaenen & Behr, 2011).  The incidence is thought to be 1 in 
5,000-10,000 in Western countries, but it is significantly more common in individuals 
with Asian ancestry (Ackerman et al., 2011). BrS also occurs about eight times more 
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frequently in men than in women (Wilde et al., 2002).  The annual risk for SCD in BrS is 
lower than in LQTS and is thought to be between 1-2% per year (Napolitano et al., 2012). 
Like LQTS, BrS displays reduced penetrance and variable expressivity.  Some 
patients may never experience symptoms, while others may experience syncope, 
palpitations, and/or SCD.  Symptoms generally present when the patient is resting or 
sleeping; however, patients usually do not become symptomatic until adulthood 
(McGorrian et al., 2013).  BrS also displays locus and allelic heterogeneity; it is 
associated with over 250 mutations in 10 different genes.  The most common genetic 
cause is a loss-of-function mutation in SCN5A, which is found in about 20% of cases. 
Like the majority of LTQS cases, BrS is inherited in an autosomal dominant manner 
(Bastiaenen & Behr, 2011; Napolitano et al., 2012).  ICD implantation is the standard 
treatment for high-risk patients. Quinidine, an anti-arrhythmic drug, is currently being 
considered to treat medium or low-risk patients.  Because fever can be a trigger for 
cardiac events, treating febrile illness with ibuprofen is another aspect of medical 
management.  Avoiding medications that can exacerbate the ST elevation is also 
suggested for patients with BrS (Bastiaenen & Behr, 2011).   
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is characterized 
by an exercised or acute emotional-induced ventricular tachycardia, which in turn can 
cause syncope, cardiac arrest, and SCD (Ackerman et al., 2011; Napolitano et al., 2012).  
The exact incidence of this condition is unknown. Morbidity and mortality are relatively 
high for untreated patients with CPVT; they have a 79% risk of having a cardiac event by 
age 40 as well as a 30% chance of SCD as the first presenting symptom. The average age 
of symptom onset is eight years of age. (Ackerman et al., 2011; Napolitano et al., 2012).   
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Two genes are currently known to be associated with CPVT. They code for the 
ryanodine receptor protein RyR2 and the cardiac calsequestrin protein CASQ2.  Both of 
these proteins are involved in the release of calcium from the sarcoplasmic reticulum 
(Napolitano et al., 2012). Mutations in RYR2 are responsible for the autosomal dominant 
form of CPVT, which accounts for about 60% of cases. CASQ2 mutations are less 
common (3-5% of cases) and cause the autosomal recessive form of CPVT (Ackerman et 
al., 2011).  The primary treatment modality for CPVT patients is pharmacotherapy with 
beta-blockers.  However, about 30% of patients still have arrhythmic events while taking 
these medications; ICD implantation has been suggested for these individuals 
(Napolitano et al., 2012). 
Hypertrophic cardiomyopathy is the most common genetic heart disease; it affects 
1 in 500 people and is characterized by variable cardiac hypertrophy, muscle fibrosis, and 
myocyte disarray within the cardiac muscle.   Patients may also experience syncope, 
dyspnea, and cardiac arrest.  Like many other cardiac conditions, HCM displays reduced 
penetrance and variable expressivity. Patients with a known genetic cause generally 
present with a more severe phenotype than patients with negative genetic testing results 
(Ackerman et al., 2011; Bos et al., 2014). 
HCM is also known as a genetically heterogeneous condition.  At least nine genes 
that code for cardiac myofilaments (sarcomeres) have been implicated in HCM 
pathogenesis, and most of the mutations found to date are unique to each family and 
inherited in an autosomal dominant manner.  The most commonly found mutations are in 
MYBPC3 and MYH7; they each account for 25-33% of all cases (Ackerman et al., 2011). 
Several studies have attempted to make genotype-phenotype correlations with the several 
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sarcomere genes associated with HCM.  While no mutation-specific correlations have 
been made, patients carrying a sarcomere mutation tended to present with a more severe 
phenotype; they generally presented at an earlier age, have a greater degree of 
hypertrophy, and have a greater frequency of SCD and family history of HCM (Lopes, 
Rahman, & Elliott, 2013).  The medical management plan for patients with HCM consists 
of symptom treatment, surveillance and prevention of complications, and may include 
pharmacotherapy, surgery, and pacemaker/ICD implantation (Cirino & Ho, 2008).  In a 
subset of patients, HCM is a feature of another genetic condition.  There are several 
muscular dystrophies as well as metabolic and mitochondrial disorders associated with 
cardiomyopathies like HCM or DCM. Although many patients with these disorders are at 
a high risk for arrhythmia and may require a pacemaker or ICD, treatment would be 
largely dependent on the specific diagnosis (Gilbert-Barness, 2004) 
Arrhythmogenic right ventricular cardiomyopathy is a type of heart disease with a 
reported incidence of 1 in 1,000-1,250 people that results in the breakdown of the 
myocardium in the right ventricle. It is characterized by ventricular arrhythmia, syncope, 
and an increased risk for heart failure and/or SCD; however, due to reduced penetrance 
and variable expressivity, only about half of mutation carriers become symptomatic 
(McNally, MacLeod, & Dellefave-Castillo, 2005). This is an important factor to consider 
when counseling patients about their risk of arrhythmia and SCD.  Exercise can be a 
possible trigger for patients with AVRC (Janzen et al., 2014). Most forms of AVRC are 
autosomal dominant; however, digenic and autosomal recessive forms do exist. 
Regardless of the inheritance pattern, AVRC displays both clinical and allelic 
heterogeneity.  The majority of genes known to be responsible for this condition are 
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desmosomal proteins, which are involved in cell-cell adhesion.  Mutations in these genes 
account for 30-70% of AVRC cases (Ackerman et al., 2011).  Treatment for ARVC is 
similar to therapy for HCM. It is focused on minimizing syncope, cardiac arrest, and 
SCD with pharmacotherapy and ICD implantation (McNally et al., 2005). 
Dilated cardiomyopathy (DCM) is characterized by enlargement of the left 
ventricle and systolic dysfunction, or reduced contractility.  Common symptoms include 
arrhythmias, heart failure with congestion, fatigue, and dyspnea. This condition is also 
characterized by age-dependent penetrance with the age of onset varying from infancy to 
adulthood.  DCM is thought to be more common than HCM; however, the exact 
incidence is unknown (Hershberger & Morales, 2007).  Most genetic forms of DCM are 
inherited in an autosomal dominant fashion, but autosomal recessive and X-linked 
inheritance patterns have also been seen.  Over 30 genes have been implicated in DCM; 
however, each gene accounts for less that 5% of the DCM cases (Ackerman et al., 2011). 
Treatment is similar to the previously described cardiomyopathies.  The main modalities 
of treatment include pharmacotherapy with antiarrhythmic drugs, ICD or pacemaker 
implantation, and heart transplantation for advanced heart failure.   
1.2 Diagnosing Cardiac Conditions  
While some affected individuals will have obvious and distinct clinical features 
that lead to a clear diagnosis, most cases are not this straightforward.  Since these ion 
channelopathies and cardiomyopathies show reduced penetrance and variable expression, 
not all mutation carriers will present with a phenotype indicative of a cardiac condition.  
It often requires a “perfect storm;” a combination of genetic predisposition and 
environmental factors, including a trigger, to set off a severe arrhythmic event that would 
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be suggestive of a cardiac disease (Janzen et al., 2014).  Therefore, a variety of tests and 
evaluations are used to help detect affect individuals with more subtle phenotypes.   
A thorough medical history can help narrow the differential diagnosis when 
screening for cardiac disease.  Important elements of the medical history include detailed 
information about any previous episodes of syncope or palpitations, such as what the 
patient was doing when (s)he become symptomatic as well as any medication (s)he was 
taking.  A family history of syncope, cardiac arrhythmia, seizures, dizziness, sudden 
cardiac arrest, or SCD can also be strongly indicative of an inherited cardiac disease.   
A medical examination is another important part of the evaluation when screening 
for cardiac disease, and can include several tests. In addition to a resting 
electrocardiogram (EKG), signal-averaged EKGs, provocative stress EKGs, Holter 
monitors, and implantable loop monitors are also used to detect cardiac arrhythmias.  
Signal-averaged EKGs look at about 400 heartbeats and can be used to detect less 
obvious arrhythmias that may be missed on a resting EKG.  A provocative stress test is 
similar to a resting EKG, but instead of remaining still, the electrical activity of the heart 
is recorded before, during, and after either exercise of varying intensity or administration 
of an antiarrhythmic drug.  This test makes it possible to pick up arrhythmias that only 
present when physically stressed and is the primary diagnostic tool used for CPVT (Behr, 
2010; Janzen et al., 2014).  A holter monitor is a portable EKG that records the electrical 
activity of the heart for 24 to 48 hours, and can be used to detect arrhythmias that are 
intermittent.  An implantable loop monitor is a small device that is placed under the skin 
and can be used to record a patient’s heart rhythm for up to three years.  These devices 
are useful if a patient’s symptoms occur less frequently (Mofrad, 2012).  An 
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echocardiogram, or an ultrasound of the heart, is another method used to identify cardiac 
conditions.  It is useful when determining if there is any structural damage, and is the 
gold standard for diagnosing HCM, DCM, and ARVC (Behr, 2010).  A cardiac MRI is a 
second diagnostic tool that allows physicians to visualize the structure of the heart for 
diagnosing certain cardiac conditions (Janzen et al., 2014).  
Genetic testing is an additional technique that is utilized to help diagnose cardiac 
disease.  In families where a member has suffered from SCD, a molecular autopsy can be 
performed.  If a familial mutation has not been previously identified in a family, DNA 
testing for a number of genetic mutations that cause inherited cardiac conditions can be 
done on DNA of the deceased individual.  If a pathogenic mutation is found, cascade 
screening of at-risk relatives can help identify other mutations carriers in the family.  
Conversely, if a familial mutation has already been identified, genetic testing for that 
specific change in the DNA can be done to diagnose the cause of death (Behr, 2010).   
1.3 Implications of Genetic Testing  
Genetic testing for ion channelopathies and cardiomyopathies is also performed 
on living patients when cardiac disease is suspected.   Before genetic testing is 
completed, however, there are several logistical and psychosocial considerations that 
need to be addressed.  One aspect to consider is the benefits and limitations of genetic 
testing.  Confirming a clinical diagnosis with genetic testing can have prognostic and 
therapeutic implications that will aid in medical management, but genetic testing is not an 
infallible technique. While genetic testing detects mutations in the majority of patients for 
some conditions like LQTS, genetic testing for other conditions yields a much lower 
positive mutation rate.  For example, mutations are only found in 20-30% of clinically 
diagnosed patients with Brugada syndrome (Bastiaenen & Behr, 2011). Therefore, a 
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negative genetic test result does not necessarily rule out a genetic cause for a patient’s 
clinical features. A second issue that must be discussed is the possibility of genetic 
discrimination.  Although the Genetic Information Nondiscrimination Act (GINA) was 
passed in 2008 to prevent genetic discrimination in the workforce and health insurance, 
there are other sectors in which genetic discrimination is not prohibited.  These areas 
include life insurance, long-term care insurance, and disability insurance.  Therefore, 
patients should be counseled to consider obtaining these types of insurance before being 
tested.   
If a patient’s genetic testing results are positive for a cardiac disease-causing 
mutation, family cascade screening is strongly recommended (Ackerman et al., 2011).  
Mutation-specific screening for at-risk family members is suggested for several ion 
channelopathies and cardiomyopathies, including LQTS, BrS, CPVT, HCM, ARVC, and 
DCM as well as several other conditions (Ackerman et al., 2011).  Family screening can 
help relieve uncertainties regarding an individuals’ carrier status as well as guide medical 
management.  An asymptomatic family member who is a mutation carrier can start taking 
preventive measures to reduce their risk of syncope, arrhythmia, and SCD.  However, 
since most of these conditions exhibit reduced penetrance and variable expressivity, some 
mutation carriers will remain asymptomatic throughout their life (Ackerman et al., 2011). 
Therefore, each individual must consider the implications of both undergoing testing and 
remaining unaware of their carrier status before making a decision. People who choose to 
undergo genetic testing list several motivations for their decision, including to find an 
explanation for family history of sudden death, to confirm a clinical diagnosis, to aid in 
medical management decisions, to alleviate concerns about risk to other family members, 
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and to comply with physicians’ or relatives’ recommendations.  A lack of information, 
denial, and fear were reasons people had reported in their decisions not to pursue genetic 
testing (Erskine et al., 2014).  
Many individuals, regardless of their age, experience psychosocial consequences 
of discovering they are a mutation carrier for a cardiac disease.  One study found that 
patients experienced significantly increased levels of heart-focused anxiety after learning 
about their genetic diagnosis of LQTS or HCM.  The three aspects of anxiety that they 
focused on are avoidance of activities thought to trigger cardiac symptoms, increased 
attention toward cardiac activity, and fear regarding heart sensations (Hamang et al., 
2012).  Even though these feelings seemed to persist over an extended period of time, 
their study showed that patients who underwent genetic counseling experienced reduced 
levels of cardiac avoidance and attention.  These findings indicate that providing accurate 
information about their condition as well as psychosocial support can help lower their 
heart-focused anxiety.   
Numerous individuals with inherited cardiac disease present with symptoms 
during childhood; therefore, a significant portion of the population undergoing genetic 
screening is under the age of 18.  In addition to the topics that should be addressed for all 
patients, there are special considerations that should be taken into account when testing 
children. Several case studies have been done to investigate the challenges health 
professionals may encounter while counseling children and adolescents regarding genetic 
testing (Callard, Williams, & Skirton, 2012; Cohen, Stolerman, Walsh, Wasserman, & 
Dolan, 2012).  Medical professionals must balance the wishes of the parents, child, and 
the medical necessity when discussing genetic testing.   
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Adolescents’ cognitive ability and maturity level are two factors that may make 
counseling them more difficult. When children refuse to be tested, it can be difficult to 
determine if it is because they are misinformed, are unable to consider the long-term 
implications of their decision, or are choosing to live with the risk of potentially being a 
mutation carrier. They may also be unwilling to comply with the lifestyle changes that 
are recommended for mutation carriers (Cohen et al., 2012).   When the parents and/or 
the child are opposed to genetic testing, it is important to ensure that they understand the 
diagnostic, prognostic, and therapeutic benefit that genetic testing may provide.  
Parents may also be resistant to testing their children.  According to Cohen, 
Stolerman et al., many parents who do not wish to have their children tested are 
concerned about the psychological impact testing would have on their children and that it 
would outweigh the benefits of knowing their genetic status (2012).  Although these 
concerns are understandable, Meulenkamp et al., have shown that learning about their 
carrier status does not affect children as significantly as some parents think it will (2008).  
They found that most children became well-adjusted to their diagnosis and were 
knowledgeable about the genetic nature and lack of cure for their condition.  Participants 
who were having trouble coping with their condition seemed less informed about their 
diagnosis and the steps that should be taken to reduce their risk of SADS.   
The authors also reported implications for counseling based on their data. First, 
they emphasized the necessity of children understanding their diagnosis as well as the 
implications of their carrier status.  Second, they recommended that children should have 
a realistic understanding regarding the how controllable the condition is.  The authors 
found that providing information on what steps should be taken to reduce their risk and 
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why these measures work will help reduce worries in carrier children.  The third 
implication is the necessity of parental support as they makes choices about how to best 
protect their children without imposing excessive limitations on their activities.  
1.4 Communicating Genetic Risk to Children  
Previous research has made it clear that children are not adults in smaller form; 
they are still undergoing cognitive development and therefore require information to “be 
tailored to their social, emotional, and cognitive development”(Sullivan & McConkie-
Rosell, 2010, p.231). For children to understand complex concepts such as genetic 
conditions, the information must be simplified to the appropriate level and communicated 
using appropriate emotional tones in an open style of communication (Sullivan & 
McConkie-Rosell, 2010).  Although minimal research has been published on how parents 
communicate risk information about cardiac diseases associated with SADS (Mangset & 
Hofmann, 2014), studies have been done to investigate how parents communicate 
diagnoses and related risk information to their children.  
These studies have similar findings regarding the communication pattern between 
parents and their children as well as the potential barriers that may affect communication.  
One study, completed by McConkie-Rosell and her colleagues, investigated how parents 
disclose risk information to their daughters who are potential carriers for Fragile X 
syndrome, a genetic condition that causes developmental disabilities primarily in males 
(2011). When asked, the girls stated that they desired a resilient communication style. 
They preferred “having an ‘actual conversation,’ the information to be staged, given with 
reassurance, normalized, and that parents be truthful, honest and knowledgeable about the 
genetic information” (McConkie-Rosell, Del Giorno, & Heise, 2011, p.59).  This finding 
correlates with the conclusions made from another study of families with children 
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diagnosed with LQTS; the majority of parents felt that it was important to know their 
children’s carrier status and be open and honest with the information (Mangset & 
Hofmann, 2014).  Another study, which explored how genetic risk information was 
discussed for a variety of Mendelian disorders, found that when information about their 
condition was disclosed gradually from an early age, children were more able to cope 
with the condition (Metcalfe, Plumridge, Coad, Shanks, & Gill, 2011). Not only did they 
have a better understanding of their condition in the long run, but they were also able to 
learn about the implications with less of a shock.  These findings emphasize the 
importance of disclosing information about a child’s diagnosis in an appropriate way.   
Even though many parents and children express desire for early and direct 
communication, it does not always occur. One fourth of the girls in the study of families 
with Fragile X reported that they became aware of their personal risk for carrying a 
mutation exclusively through indirect communication (McConkie-Rosell, Heise, & 
Spiridigliozzi, 2009).  Metcalfe and her colleagues also found that most parents delayed 
discussing their genetic risk information with their children for as long as possible 
(2011). After interviewing the parents, the authors of these studies proposed several 
potential barriers to the open communication the families preferred. The need to protect 
their children, the shock of the diagnosis, and feelings of guilt, fear, and grief were all 
reasons parents delayed or avoided discussing genetic risk information with their children 
(Metcalfe et al., 2011).  Other possible barriers to communication include hesitation 
about when to disclose, how to phrase the complex information and the implications for 
the child’s future as well as uncertainty regarding what the child will be able to 
understand (McConkie-Rosell et al., 2011). Batte et al. (2015) made similar findings 
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when they surveyed families with a history of HCM.  They identified an accurate 
understanding of the risk for other family members as a propeller of familial 
communication and dysfunctional family dynamics as a factor that may hamper 
communication within a family.  Previous articles have recommended several activities 
that healthcare professional can partake in to help parents with the disclosure process.  
Discussing communication styles the family currently uses, brainstorming possible 
questions the children may ask, exploring how to describe the information using language 
the child will comprehend, and allowing the parents to practice dialoging the 
conversation are all helpful suggestions (McConkie-Rosell et al., 2011). However, it is 
not known what type of guidance is most wanted by parents of children who have cardiac 
conditions with a risk of SADS.   
Some of the parents expressed a desire for more instruction on how to talk to their 
children about genetic risk information during the interview process. One of the fathers 
stated: “Perhaps the next step for us now is to get some guidance on how to talk about it 
without making her very scared” (Mangset & Hofmann, 2014).  Surveying parents whose 
children have a variety of cardiac diseases associated with SADS will provide more 
detailed information on what exactly families who are adapting to these conditions need 
from healthcare professionals.
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CHAPTER 2: Exploring How the Risk of Sudden Cardiac Death is Discussed in 
Families with a Diagnosis of a SADS Condition1  
2.1 Abstract 
Sudden arrhythmic death syndrome (SADS), where death is secondary to cardiac 
arrhythmia, is associated with several cardiac ion channelopathies, including long QT 
syndrome and Brugada syndrome, as well as cardiomyopathies such as hypertrophic 
cardiomyopathy and dilated cardiomyopathy.  Many of these conditions often present in 
childhood or adolescence.  This study investigates how diagnoses of cardiac diseases 
associated with SADS are communicated within families.  A questionnaire was 
distributed through cardiac disease-focused support groups and organizations.  Data from 
114 parents who have a child with a SADS condition were used for analysis. Based on 
the responses, parents explained the risk of SADS in a straightforward manner and 
related the risk to the importance of compliance with the prescribed treatment.  
Participants also found it difficult to determine and enforce lifestyle modifications, 
manage the families’ emotional reactions, convey the seriousness of the information 
without scaring their children, and discuss the risk of SADS during these conversations.  
Concerns regarding disease progression, length and quality of life, and treatment failures 
and complications were also expressed.   Healthcare providers, the Internet, other
                                                           






 affected people, visual aids, and personal experience were all reported to be helpful for 
discussing the SADS condition with their children. Services and resources that were 
requested were children’s support groups, a counselor or psychologist, and child-oriented 
materials.  Increased understanding of how families discuss children’s diagnosis of SADS 
conditions will equip healthcare providers with the information to address parental 
concerns and help facilitate discussion of the condition between parents and their 
children.  
2.2 Introduction 
Sudden arrhythmic death is a subtype of sudden cardiac death (SCD) where death 
is secondary to a cardiac arrhythmia.  An individual’s death is attributed to sudden 
arrhythmic death syndrome (SADS) in cases of SCD where a structural heart defect is not 
present (Vyas & Lambiase, 2013).  Numerous studies have investigated the incidence of 
SADS; the estimated prevalence of SADS ranges from 0.16-0.24 per 100,000 people per 
year in the general population to 0.76 per 100,000 people per year in individuals aged 14-
35 (McGorrian et al., 2013, Vyas & Lambiase 2013).   
 A genetic predisposition for cardiac disease has been found in up to 50% of 
families with a history of SADS (Vyas & Lambiase, 2013). A subset of cardiac 
conditions, collectively known as ion channelopathies, affect the electrophysiology of the 
heart without altering the actual cardiac structure.  Long QT syndrome (LQTS), Brugada 
syndrome, and catecholaminergic polymorphic ventricular tachycardia (CPVT) are three 
of the more common ion channelopathies associated with a risk of SADS (Behr, 2010; 
Vyas & Lambiase, 2013). As a group, ion channelopathies are thought to be responsible 






as hypertrophic cardiomyopathy (HCM), arrhythmogenic right ventricular 
cardiomyopathy (ARVC), and dilated cardiomyopathy (DCM) have also been associated 
with SADS and are thought to be responsible for 10-20% of SADS cases (Behr, 2010).   
While the symptoms patients experience vary among diseases, there is significant 
overlap in the above conditions.  Both the ion channelopathies and the cardiomyopathies 
are characterized by arrhythmia, syncope, seizures, fatigue, and cardiac arrest (Ackerman 
et al., 2011).  In addition, the cardiomyopathies are characterized by specific structural 
abnormalities and have a risk for congestive heart failure.  Most mutations are inherited 
in an autosomal dominant manner, but other inheritance patterns do exist for these 
conditions.  Both classes of cardiac diseases also display reduced penetrance and variable 
expressivity.  Therefore, not everyone who carries a mutation will develop symptoms.  
The morbidity and mortality rate is dependent upon a multitude of factors.  In addition to 
the clinical diagnosis and specific mutation, a patient’s age, sex, and lifestyle choices can 
also influence their risk for developing symptoms (Ackerman et al., 2011).  There is also 
a notable range in mortality rates for the above conditions. The annual risk of sudden 
cardiac death is thought to be 1-2% for Brugada syndrome (Napolitano et al., 2012).  In 
contrast, the mortality rate for the untreated LQTS population may be as high as 50% 
(Ackerman et al., 2011).   
 There are similarities in the suggested medical management for the above 
cardiomyopathies and ion channelopathies as well. Treatment mainly consists of 
pharmacotherapy with beta-blockers and other medications, lifestyle modifications (such 
as exercise restrictions), and avoidance of drugs that increase the likelihood of arrhythmic 






or a pacemaker implanted (Ackerman et al., 2011; Napolitano et al., 2012). Some patients 
with cardiomyopathy may require a heart transplant if they develop advanced heart 
failure (Ackerman et al., 2011).  
Medical professionals currently utilize a variety of tests and evaluations to 
diagnose these conditions, including documentation of a detailed family and medical 
history; a physical exam, consisting of an electrocardiogram, echocardiogram, and 
cardiac MRIs; and genetic testing (Behr, 2010; Janzen et al., 2014).    
Many individuals with inherited cardiac disease present with symptoms during 
childhood; therefore, parents often find themselves having to explain the diagnosed 
cardiac condition to their children.  Previous research has illustrated that children are still 
undergoing cognitive development and therefore require information “be tailored to their 
social, emotional, and cognitive development” (Sullivan & McConkie-Rosell, 2010, 
p.231). In order for children to understand complex concepts such as genetic conditions, 
the information must be simplified to the appropriate level and communicated using 
appropriate emotional tones in an open style of communication (Sullivan & McConkie-
Rosell, 2010).  However, minimal research has been published on how parents 
communicate risk information about cardiac diseases associated with SADS (Mangset & 
Hofmann, 2014).  Surveying parents of these children would provide insight into this 
information, which can then be used to equip healthcare providers in helping parents have 
these crucial conversations with their child.   Our study was expected to fill a gap in the 
current knowledge that will benefit cardiologists, genetic counselors, and other healthcare 






allow healthcare professionals to better understand how to address these issues with the 
parents.    
The primary objectives of this study included investigating how parents 
communicate with children about the children’s diagnoses of cardiac diseases associated 
with SADS, exploring how the risk of sudden cardiac arrest is discussed between the 
parents and their affected children, and determining which aspects of these conversations 
parents find most difficult to communicate to their child.  We hypothesize that numerous 
factors, including the children’s specific diagnosis as well as the families’ experiences 
with the condition and its associated symptoms have influenced how parents 
communicate their children's diagnosis to them.  
2.3 Materials and Methods 
 This research study collected quantitative and qualitative data from parents of 
children who have a diagnosis of a cardiomyopathy associated with SADS.  Participants 
were recruited through various organizations and Facebook groups targeted to families 
with children affected by the previously described conditions.  Individuals over the age of 
18 who had at least one child with a cardiomyopathy associated with a risk of SADS and 
could comprehend the medical & technical information in the questionnaire were eligible 
to participate in this study.   
An invitation to participate (Appendix C) as well as a link to the survey 
(Appendix D) hosted on surveymonkey.com was distributed through several avenues.  
The SADS Foundation, Hypertrophic Cardiomyopathy Association, and the 
Cardiomyopathy Foundation were contacted via email to explain the purpose of the study 






three organizations were willing to invite their members to participate and did so via their 
respective electronic mailing lists.  In addition, a link to the invitation to participate letter 
and survey were posted on various Facebook groups (Appendix B).  The links were 
posted in September and October of 2014, and were available until December, 2014.   
 The survey consisted of multiple choice and open-ended questions that inquired 
about demographic information as well as the diagnostic process for their children’s 
cardiomyopathy, how both the diagnosis and the risk of SCA is discussed between the 
parents and their children, and what aspects of these conversations are most difficult. 
Responding to each question was voluntary, which allowed participants to skip questions 
they did not wish to answer.  Upon completion of the survey, participants were invited to 
provide their contact information to enter their name in a drawing for a $25 gift card to a 
location of their choice.  
 Quantitative analysis was performed using statistical analysis software (SAS) 
base 9.4. Fisher’s exact test with and without Monte Carlo estimates as well as the 
extended Cochran-Mantel-Haenszel correlation statistic were used to identify significant 
relationships within the survey group. A 0.05 level of significance was used for all 
analyses.  In addition, frequencies and percentages were calculated for each question. 
Qualitative data was analyzed by the principal investigator to identify recurring themes 
using Grounded Theory methods. This research study was approved by the Institutional 
Review Board, Office of Research Compliance, of the University of South Carolina, 









   2.4.1 Participant Demographics  
A total of 114 participants completed the survey, all of which met the eligibility 
criteria.  Respondent demographics are displayed in Table 2.1 and 2.2. The majority of 
participants were Caucasian (n = 95, 83%) females (n = 98, 86%) between the ages of 30 
and 49 (n = 78, 68%) who had completed at least some college (n = 88, 77%) and were 

























Table 2.1 Participant Demographics  
  Frequency  
(N = 114) 
Percentage (%) 
Gender     
 Female 98 86 
 Male 6 5 
 Prefer not to answer 10 9 
Age     
 <20 0 0 
 20-29 5 4 
 30-39 33 29 
 40-49 45 40 
 50-59 17 15 
 60-69 4 3 
 >70 0 0 
 Prefer not to answer  10 9 
Education level    
 Less than high school degree 0 0 
 High school degree or 
equivalent 
16 14 
 Some college, but no degree 22 19 
 Associate degree 13 11 
 Bachelor degree 28 25 
 Graduate degree 25 22 
 Prefer not to answer 10 9 
Ethnicity     
 American Indian or Alaskan 
Native 
2 2 
 Asian or Pacific Islander 1 1 
 Black or African American 0 0 
 Hispanic or Latino 3 3 
 White/ Caucasian 95 83 
 Prefer not to answer  13 11 
Relationship status    
 Married 78 68 
 Widowed 1 1 
 Divorced 5 4 
 Separated 4 4 
 Domestic partnership or civil 
union 
4 4 
 Single 10 9 







The majority of participants’ children had either HCM (n = 61, 54%) or LQTS (n 
= 39, 34%). The most common age range at diagnosis was zero to three years (n = 32, 
28%), followed by 10 to 12 (n = 19, 17%) and 13 to 15 (n = 19, 17%). The majority of 
children were between 10 and 18 years of age at the time the survey was completed, with 
the most commonly selected age range being 13 to 15 years. There were a relatively 
equal number of reported male (n = 58, 51%) and female (n = 56, 49%) children.  For 
participants who had multiple children affected with a cardiomyopathy, data is displayed 
for their first child diagnosed (Table 2.2).   
Table 2.2 Children Demographics  
  Frequency (N = 114) Percentage (%) 
Gender     
 Male 58 50 
 Female 56 50 
Diagnosis     
 LQTS 39 34 
 Brugada 5 4 
 ARVC 1 1 
 HCM 61 54 
 DCM 2 2 
 CPVT 2 2 
 Unknown 2 2 
 Other 2 2 
Age at diagnosis    
 0-3 32 28 
 4-6 6 5 
 7-9 16 14 
 10-12 19 17 
 13-15 19 17 
 16-18 13 11 
 19-21 4 4 
 22+ 5 4 
Current age    
 0-3 8 7 
 4-6 8 7 
 7-9 9 8 
 10-12 20 18 
 13-15 24 21 
 16-18 15 13 
 19-21 11 10 
 22+ 13 11 







   2.4.2 Experience with Symptoms and Treatment 
The most commonly selected first presenting symptom was arrhythmia (n = 23, 
21%), followed by syncope (n = 11, 10%).  All other symptoms were experienced at the 
presentation of the condition in fewer than 10% of cases.  Notably, 43% of the 
participants reported that their first child (if multiple children are affected) is 
asymptomatic.  When questioned about the symptoms experienced by their child(ren) to 
date, arrhythmia (n = 45, 40%), dizziness (n = 43, 38%), and syncope (n = 27, 24%) were 
the most commonly reported symptoms. Lifestyle modifications (n = 72, 63%) and 
medications (n = 71, 62%) were the most frequently selected treatment options.  ICDs 
and pacemakers were utilized by 27% and 9% of the respondents’ children, respectively 
(Table 2.3) 
Table 2.3 Symptoms and Treatment 
  Frequency  Percentage (%) 
First presenting symptom  n = 109  
 Syncope 11 10 
 Arrhythmia  23 21 
 Sudden Death 6 6 
 Seizure 1 1 
 Heart murmur 9 8 
 Shortness of breath 3 3 
 Asymptomatic 47 43 
 Other  9 8 
Symptoms experienced to date   N = 114  
 Syncope 27 24 
 Arrhythmia 45 40 
 Seizure 11 10 
 Sudden Death 6 5 
 Sudden Cardiac Arrest 7 6 
 Dizziness 43 38 
 Shortness of Breath  6 5 
 None  13 11 
Current treatment  N = 114  
 Medication 71 62 
 Lifestyle Modifications  72 63 
 Pacemaker 10 9 
 ICD 31 27 
 Other  11 10 






   2.4.3 Parental Concern Regarding Their Children’s Cardiomyopathy 
 A total of 98 participants responded when asked the question, “What is your 
biggest concern for your child(ren) regarding their condition?”.  The majority of 
participants reported concerns were related to disease progression, especially SCA.  
Concerns regarding their children’s length and quality of life, specifically the number of 
medical appointments, sports restrictions, and the children’s emotional well being, were 
also commonly expressed.  A third set of concerns surrounded their children’s treatment.  
Respondents were worried about the lack of compliance by their children, as well as 
faulty treatments or treatment complications.   
   2.4.4 Communication Regarding the Diagnosis  
Participants were questioned about who was involved in explaining the diagnosis 
to the children, the time frame that was taken to explain the diagnosis, and what topics 
were focused on in initial and subsequent conversations.  The mothers of the children 
were the most frequently involved in the initial explanation (n = 90, 79%), followed by 
the physicians (n = 75, 66%), and then the fathers (n = 51, 45%).  A significant 
correlation was found between the diagnosis and whether or not the father was involved 
in the explanation to the child (p =.0225) through the use of Cochran-Mantel-Haenszel 
statistics.  While close to 60% of fathers were involved in the explaining a diagnosis of 
LTQS to their children, less than a third of fathers who had children diagnosed with 
HCM were involved in the explanation.   
The majority of parents explained the diagnosis over a period of months or years 
(n = 62; 54%); however, a notable number of parents reported that the initial explanation 






Fisher’s exact test revealed a statistically significant association between the age of 
diagnosis and the time frame of the initial explanation (p < .0001).  Parents were more 
likely to stretch the explanation over months or years if the child was diagnosed at a 
younger age.  Approximately 10% of respondents selected two or more time frames, so 
the total percentage for the time period of the diagnosis does not add up to 100 percent. A 
third of the participants stated that the children’s diagnoses were not discussed regularly; 
the other respondents reported discussing it daily, weekly, and monthly in approximately 
equal numbers (Table 2.4)   
Table 2.4 Explanation of the Diagnosis  
  Frequency Percentage (%) 
People involved in the explanation of 
the diagnosis 
 N = 114  
 Mother  90 79 
 Father 51 45 
 Other Relative  8 7 
 Physician 75 66 
 Genetic Counselor 19 17 
 Other  5 4 
Time period of explanation of 
diagnosis 
  
n = 101 
 
 Days 41 41 
 Weeks 15 15 
 Months 28 28 
 Years 34 34 
Frequency of discussion   n = 102  
 Daily  21 21 
 Weekly 23 23 
 Monthly 27 27 
 Not discussed regularly 34 33 
 
 
The majority of topics were discussed in similar frequencies in the initial and 
subsequent conversations.  Possible symptoms and medical management were the most 
commonly discussed topics in both the initial and follow-up conversations (60%-72%). 
The most notable difference between the initial and follow-up conversations was the 36% 






in subsequent conversations when compared with the initial explanation.  Respondents 
who selected “other” for both the initial and follow-up conversations mainly discussed 
topics related to medical management, such as participation in sports and surgeries.  
Figure 2.1 displays the percentage of participants that discussed each of the topics during 
the initial explanations and following conversations.   
 
 
Figure 2.1 Topics Discussed During Initial Explanation and Subsequent Conversations  
 
Statistical analysis was conducted to investigate if any significant relationships 
existed between what was discussed in the initial and follow-up conversations and the 
children’s age at diagnosis, symptoms experienced to date, and the parents’ 
understanding of their children’s risk of SCA.    The use of Cochran-Mantel-Haenszel 
Statistics revealed a statistically significant relationship between the child’s age at 
diagnosis and whether or not genetics (p = .0331) and how the condition specifically 
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affects the heart (p = .0151) were discussed in initial conversations. As the age of 
diagnosis increased, parents were more likely to discuss the genetic aspect of the 
condition.  While there was no linear relationship between the age of diagnosis and the 
frequency at which parents discussed how the condition specifically affects the heart, 
parents were most likely to describe this aspect of the condition when their child was 
diagnosed between the ages of seven and 15.  
Utilization of Fisher’s exact test revealed statistically significant associations 
between what was discussed in subsequent conversations and whether or not their 
children were symptomatic.  Symptoms (p = .0053), how the condition affects the heart 
(p = .0192), medical management (p = .0195), and other family members with the same 
condition (p = .0296) were all more likely to be discussed in follow-up conversations if 
the participants’ children were symptomatic.   
Free-response questions were analyzed to identify what triggers these 
conversations and what aspects of these conversations were most difficult.  The majority 
of participants reported triggers related to medical management, such as limitations from 
physical activity, an appointment with the cardiologist, medication, or an ICD 
implantation.  Physical symptoms felt by their children, the psychosocial and emotional 
impact of the condition, and questions or comments made by the children were three 
other commonly reported triggers.  Furthermore, a significant correlation (p = .0115) 
between the diagnosis and frequency of children’s questions and comments being 
reported as a trigger was identified using Monte Carlo estimate for Fisher’s exact test.  
While over 20% of parents whose children have LQTS reported it as a trigger, less than 






for conversations regarding the diagnosis.  No other associations between the reported 
triggers and the child’s diagnosis were found.   
Four main answers were identified from the parent’s responses to the question, 
“What were the more difficult aspects of these conversations with your child?” 
Approximately one half of participants stated that discussing medical management, 
especially surgery and lifestyle stages, were most difficult for them. One mother reported:  
Lifestyle modifications [have]been the hardest!! Both of my children love, 
love, love to play competitive sports. When the Dr. told both of my 
children they could not play it was the beginning of the emotional 
rollercoaster. My son whom loves football cried for hours. My daughter 
who loves volleyball was simply a wreck. 
A second set of answers was related to the psychosocial and emotional 
implications of the condition.  In addition to their personal concerns, some participants 
stated that their children were experiencing anxiety attacks or struggling with “being 
different.” One parent reported that her child was prescribed Zoloft to help manage her 
fear of her ICD firing.  Multiple respondents also mentioned struggling with balancing 
information about the condition when talking with their children.  In addition to having 
trouble explaining the condition in an age-appropriate way, parents found it difficult to 
“foster appropriate concern” without making their children constantly worry.  Lastly, 
several parents said that they struggled with discussing the possible symptoms, 
specifically SCA. While there is not sufficient evidence that a statistically significant 
correlation between the diagnosis and reported difficult aspects of these conversations 






difficulty discussing medical management trends toward significance (p = .0586) and 
may warrant further investigation.   
   2.4.5 Risk of SADS  
A total of 112 participants responded to the questions regarding their 
understanding and level of concern regarding their children’s risk of SADS.  Most 
respondents stated that they thought their children either had a low (n = 42; 38%) or 
moderate (n = 46; 41%) risk of SADS.  However, the majority of parents (n = 59; 53%) 
expressed that they were very concerned about their children’s risk of sudden death.  
Four participants stated that they were not concerned about their children’s risk of 
SADS.  Of these respondents, two of them stated that they understood their children as 
being not at risk for SADS.  Both of the children of these parents had a diagnosis of 
HCM, were diagnosed in between the ages of 13 and 18, are currently 16 or older, have 
only experienced either arrhythmia or a heart murmur, and are currently being treated 
with either medication or an ICD. The other two participants who expressed no concern 
for their children’s risk of SADS reported their understanding of the risk for SADS to be 
either low or moderate risk. For the parent who selected low risk, her children have a 
diagnosis of Brugada, are asymptomatic, and are not being treated for their condition. For 
the parent who selected moderate risk and no concern, his or her children have a 
diagnosis of LQTS; have experienced syncope, arrhythmia, seizures, and dizziness; and 
are being treated with medication, an ICD, and lifestyle modifications.  Additionally, 
these children’s other parent has also been diagnosed with LQTS, but was identified as 







Figure 2.2 Parental Understanding of the Risk of SADS for their Children  
 

























Statistical analysis was conducted to investigate if the participants’ understanding 
of the risk of SADS correlated with the symptoms the children have experienced or the 
parent’s level of concern regarding SADS.  Cochran-Mantel-Haenszel statistics revealed 
a correlation between the parents’ understanding of their children’s risk of SCA and 
whether or not their children have experienced arrhythmia (p = .018).  Parents whose 
children have not experienced arrhythmia most often reported their children as having a 
low risk for SCA.  In contrast, parents whose children have experienced arrhythmia most 
frequently stated that they felt that their children had a moderate risk of SCA.  Utilization 
of the Monte Carlo estimate for Fisher’s exact test identified a correlation between the 
parents’ understanding of their children’s risk of SCA and their level of concern 
regarding SCA (p = .0021).  The greater the parents’ perceived their children’s risk of 
SCA to be, the more likely they were to report a higher level of concern about this risk.   
Approximately 64 percent of respondents (n = 69) stated that they have 
specifically discussed the risk of sudden cardiac death with their children. When 
questioned about what prompted these conversations, the most commonly reported 
reasons were the diagnosis (61%) and healthcare appointments (49%).  Both the child 
experiencing a symptom and a family member having an event prompted discussion 
about SADS approximately one-third of the time (Figure 2.3).  About 23% of 
respondents listed other experiences, such as Facebook support groups or events 
surrounding medical management, which prompted discussion about the risk of SADS.   
Out of the 39 respondents who stated that they have not discussed this risk, the majority 
said it was because their children were too young and or they did not want to scare their 






Table 2.5 Discussions Concerning the Risk of SADS  
  Frequency Percentage (%) 
Have you discussed the 





n = 108 
 
 Yes 69 64 
 No 39 36 
Events that prompted 




n = 69 
 
 Diagnosis 42 61 
 Child experienced a symptom 23 33 
 Family member had an event 22 32 
 Other member of the community 
had an event 
7 10 
 A healthcare appointment  34 49 
 Other  16 23 
 
 
Out of the 69 respondents who have specifically discussed the risk of SCA with 
their children, 53 (77%) responded when asked about how they explained the risk of SCA 
to their children and what was most difficult about these conversations.  Although the 
participants’ answers were highly situation dependent, there were several responses that 
were repeatedly expressed.  When explaining the risk of SCA to their children, 
participants most frequently focused on how the risk of SCA was the reason for the 
necessity of the treatment the children were undergoing.   The possible symptoms and 
what actions to take if the children felt symptoms were also answers that were repeatedly 
reported.  In addition, a number of parents used examples they felt their children could 
relate to, such as a professional athlete experiencing a SCA while being active or a 
relative who has previously experienced an event.  Many parents also commented on the 
manner in which they discussed the risk of SADS. Phrases such as “straight and to the 
point,” “Blatantly. I didn’t fluff it, ” and “I told it like it is” were commonly stated.  






way to go.” Additionally, numerous participants reported explaining the information at a 
developmentally appropriate level. 
Several themes were identified in responses to the question “What was the hardest 
aspect of these conversations for you as a parent?”  The majority of parents felt that 
discussing the possibility of death and the emotional toll it has on both the parents and 
children was most difficult.  Thoughts such as: “I'm talking about my child dying. Every 
single day I worry it's his last. Every. Single. Day.” and “seeing the fear in her eyes that 
she will die suddenly like her brother” were commonly expressed.  Many parents also 
felt that it was difficult to determine appropriate lifestyle modifications and enforce them.  
For example, one mother stated that “seeing the pain in his eyes and feeling his heart 
break when his dream of college baseball was taken due to restriction in competitive 
sports” was the hardest part of these conversations.  Several parents also struggled with 
balancing the information they discussed with their children. In addition to “keeping [the 
conversation] at a developmentally appropriate level,” parents found it hard to inform 
their children about the seriousness of the condition without terrifying them.  Lastly, a 
number of parents who also had a cardiomyopathy diagnosis reported struggling with 
feeling guilty for “passing it on” to their children.    
   2.4.6 Resources 
Participants were also asked two questions regarding the use of resources when 
discussing their children’s condition with them.  Approximately 75% (n = 85) of 
participants responded when asked about what resources they found most helpful.  The 
majority of respondents stated that they found healthcare professionals to be helpful in 






other professionals, such as genetic counselors, were also included.  The Internet, 
specifically the SADS and HCMA websites, was the second most frequently stated 
resource that was thought to be helpful with the explanation. Participants also reported 
other affected people; books, visual aids, and pamphlets; and personal experience to be 
helpful with the explanation.  A total of 71 participants responded when asked about what 
other resources would have been helpful to explain their children’s diagnosis to them.  
The two most common responses were other affected people, specifically local support 
groups and peer groups for their children; and a counselor or psychologist to help cope 
with the diagnosis.  Children-directed resources, such as storybooks or videos, were a 
third repeatedly expressed desire.   
2.5 Discussion 
Little research has been done to investigate how parents communicate with their 
children about their children’s diagnosis of a cardiomyopathy associated with SADS.  
Based on data gathered from a survey completed by 114 parents with one or more 
children who have a diagnosis of a cardiomyopathy associated with SADS, this study was 
able to characterize the concerns parents had for their children related to their condition; 
the details of the initial explanation and follow-up conversations, such as who was 
involved, what was discussed, and the time frame in which it was discussed; and the 
aspects of these conversations that the parents found to be difficult. Furthermore, the 
responses from participants gave insight into the parents’ perspective of their children’s 
risk of SADS, how the parents discussed this risk with their children, and what aspects of 






were informative about the resources that were both thought to be helpful and were 
desired, but not accessed.   
   2.5.1 Parental Concern  
Three themes emerged when participants were asked what their biggest concern 
for their children regarding their condition.  Most parents expressed concern about 
disease progression. If one or more of their children were asymptomatic, they were 
concerned about the development of symptoms.  If their children were already 
symptomatic, their primary concerns were about experiencing SCA or requiring a 
transplant.  A second theme was parental concern regarding their children’s length and 
quality of life.  Not only were parents worried about how long their children would live, 
but they also were concerned about how the number of healthcare appointments and 
lifestyle modifications would affect their daily life and emotional health.  The last major 
identified theme was related to treatment; parents expressed concern about faulty 
treatments, treatment complications, and noncompliance by their children.  While many 
of these concerns may be more difficult to address, parents in previous studies have made 
suggestions that have helped alleviate some of their concerns. These include having their 
children carry a cell phone, educating other caregivers and educators about the condition 
and associated risks, and teaching their children how to identify and avoid triggers 
(Farnsworth, 2006).  Including recommendations such as these when disclosing 
children’s diagnoses to their parents may help reduce the amount of anxiety they 








   2.5.2 Communication Surrounding the Cardiomyopathy  
 Parents provided a variety of information regarding how the child’s diagnosis was 
discussed within their family, including the details of the initial explanation as well as 
subsequent conversations about the condition. The children’s mothers were significantly 
more likely than their fathers to be involved in the explanation of the diagnosis to their 
children.  Although these results may in part be due to the fact that 86% of respondents 
were female, these findings are consistent with those found by D’Agincourt-Canning, 
who concluded that women are more likely to be responsible for communicating health-
related information to other family members (2001). Interestingly, a correlation was 
found between the diagnosis and fathers’ involvement in the explanation.  Fathers whose 
children had a diagnosis of ion channelopathy were almost twice as likely to be involved 
in the explanation when compared to fathers whose children had a diagnosis of 
cardiomyopathy.  
 In agreement with recommendations made by multiple studies, children’s 
diagnoses were most commonly explained to them gradually over a period of time 
(Mangset & Hofmann, 2014; Metcalfe et al., 2011; Anderson, 2008).  A significant 
proportion of respondents stated that the initial explanation occurred over a period of 
days. Further investigation revealed that the initial explanation was more likely to occur 
over a shorter period of time as the age of diagnosis increased. This may be due to the 
fact that older children are more capable of understanding and digesting a greater amount 
of complicated information in a shorter period of time.   
 The most frequently discussed topics in both the initial and subsequent 






children were taking medication or have lifestyle modifications as a result of their 
condition, this is to be expected.  Additionally, it makes sense for parents to want to 
explain what their children may experience. Two expected trends were found regarding 
the discussion of the genetic component of the condition with their children.  A positive 
correlation was found between the age of diagnosis and the frequency at which genetics 
were discussed in the initial conversation; this is not surprising since more parents likely 
felt that their children could understand the information if they were older.  Regardless of 
age at diagnosis, parents more frequently discussed genetics in subsequent conversations.  
Many parents may not have considered this information immediately relevant to their 
children.  They also may have chosen to wait until their children are older because they 
felt their children were too young to understand such a complex concept.  A significant 
correlation was also found between several topics discussed in follow-up conversations 
and whether or not their children were symptomatic. Possible symptoms, medical 
management, other family members with the condition, and how it specifically affects the 
heart were all reiterated more frequently during follow-up conversations in families 
whose children were symptomatic.  This suggests that these aspects of the diagnosis may 
be less of a focus for the families whose children are asymptomatic.  
 The most commonly reported trigger for the conversations surrounded medical 
management, such as restrictions from physical activities, medications, and medical 
appointments.  This is to be expected because these lifestyle changes and interactions 
with medical professionals have a daily impact on the lives of both the children and their 
parents.  A significant correlation was identified between children’s comments and 






have LQTS were over four times more likely to report children’s comments and 
questions as a trigger compared to parents whose children have HCM.  This may be due 
to the fact that children with HCM were twice as likely to be asymptomatic as children 
with LQTS; it would be expected for children to initiate conversation about their 
diagnosis more frequently if they were experiencing symptoms.   
The most commonly reported aspects of these conversations that parents found 
difficult were related to medical management, the psychosocial and emotional 
implications of the condition, determining the appropriate amount and type of 
information, and possible symptoms, especially SCA.  Not only did parents have 
difficulty enforcing the necessary limitations on physical activity, but many parents also 
reported uncertainty regarding which lifestyle modifications were truly necessary.  
Difficulty in determining appropriate lifestyle modifications was also reported in a study 
by Burns-Pentecost, who interviewed parents whose children had a recent diagnosis of 
LQTS (2013).  Although not statically significant, a notable difference was found 
between the child’s diagnosis and whether or not the parents found conversations 
surrounding medical management difficult.  This difference may be due to the different 
treatments the children were undergoing and merits further investigation.  
Participants also reported these conversations to be emotionally and psychologically 
difficult for both the parents and the children.   The participants reported that both they 
and their children experienced fear regarding the children’s physical health, as well as 
concern regarding quality of life and ability to cope with the implications of their 
condition.  Specifically, some parents reported that their children struggled with “feeling 






similar findings through interviews with children with an ICD and their parents (2013).  
In addition to feeling different than their peers, many children also expressed fear of the 
possibility of being shocked by their ICD.  In contrast, only one participant reported 
being concerned about being different from his peers in a study done by Meulenkamp, 
who interviewed children who were carriers of LQTS, HCM, and familial 
hypercholesterolemia (2008).  These conflicting results suggest that there may be 
additional psychosocial issues to address in the high-risk population being treated with an 
ICD compared to the patients who do not have an ICD or pacemaker.  
Struggling with determining the appropriate way to convey information about the 
condition and the associated risks was a third theme that was identified in the 
participants’ responses.  In addition to making the information age-appropriate, parents 
were also unsure about how to explain the risks in a way that would not scare their 
children, but would make them understand the risks and be compliant with the 
recommended treatment. Several studies have underscored the importance of disclosing 
the information in an age-appropriate manner (Anderson, 2008; McConkie-Rosell, 2009).  
Being aware of the fact that parents are experiencing difficulty with conveying the 
diagnosis and associated risks in a manner that is developmentally appropriate and will 
instill appropriate concern will give healthcare providers the opportunity to proactively 
counsel parents on the disclosure process.  Lastly, the fourth major recurring aspect that 
parents found difficult to discuss were the associated symptoms of the condition.  








   2.5.3 The Risk of SADS  
In addition to exploring how a diagnosis of a cardiomyopathy or ion 
channelopathy associated with SADS is discussed in general, this study also investigated 
specifically how the risk of SADS is viewed and addressed.   A positive correlation was 
found between the parents’ understanding of their children’s risk of SADS and their level 
of concern regarding this risk.  This is to be expected; if parents think their children have 
a higher risk for SADS, they are more likely to be more concerned about this risk.  Even 
though this association was identified, it is important to note that while most parents 
viewed their children’s risk for SADS as either low or moderate, the majority of parents 
were still very concerned about this risk.  These results agree with the data obtained by 
Hendricks et al., who found that most parents of children with LQTS were highly 
concerned about the possibility of sudden death (2005).   
 The majority of participants had previously discussed the risk of SADS with their 
children.  Several triggers were reported when asked what prompted these conversations; 
the more common being the diagnosis itself and healthcare appointments.  Other triggers, 
such as the child or someone else experiencing a symptom, Facebook support groups, and 
events related to medical management were also reported.  The most common reasons for 
not discussing this risk were that their children were too young or that the parents did not 
want to scare them.  These explanations are similar to the responses given by parents of 
children with LQTS and HCM in the study conducted by Meulenkamp (2008), who also 
found that a minority of parents chose to limit the amount of information they revealed to 






Parents who had discussed the risk of SCA with their children were asked about 
how exactly it was communicated.  Framing the risk of SADS as the reason for treatment, 
the possible symptoms, and what steps need to be taken if the children experience 
symptoms were the most commonly discussed topics.  Several parents who related the 
risk of SADS to the importance of treatment commented that this approach was their way 
of encouraging compliance with the recommended lifestyle modifications and 
pharmaceutical interventions.  This approach may be helpful for parents whose children 
are resisting the recommended treatment plan and are old enough to comprehend the 
connection.  The participants who commented on the manner in which they described the 
risk of SADS stated that they explained the risk directly and honestly. These responses 
are in accordance with previous studies that investigated how children prefer to learn 
about the risks associated with a genetic condition (Rowland & Metcalfe, 2013; 
Meulencamp, 2008).  These investigators concluded that a straightforward explanation 
helped both the children and the parents cope with the diagnosis.     
There was overlap in the responses when parents were asked what they found to 
be the most difficult about these conversations compared to discussion about the 
diagnosis in general. When specifically discussing the risk of SCA, most people stated 
that they found discussing death and emotional implications it has on the family most 
difficult. Considering that many parents report experiencing fear regarding their 
children’s risk of SCA, this was expected (Farnsworth, 2006). Parents found it difficult to 
determine the correct balance of information to share with their children during these 
conversations as well.  An emotion that parents struggled with during conversations 






for passing the condition on to their children.  Feelings of guilt have been identified in 
affected parents with children who had a LTQS diagnosis in previous studies (Burns-
Pentecost, 2013).  Heightened awareness of the possibility of parental guilt in the 
healthcare community may increase the likelihood of providers proactively addressing it 
at the time of a child’s diagnosis.   
   2.5.4 Resources  
 This study asked participants what resources they found to be helpful when 
communicating their children’s diagnosis to them as well as what additional resources 
they would have liked.   Cardiologists, websites of organizations such as HCMA and 
SADS, other affected people, books and pamphlets, and personal experience were all 
reported to be helpful for discussing the diagnosis with their children.  The most 
commonly requested resources were related to helping their children better understand 
and cope with the diagnosis and included: local or peer support groups for their children, 
a counselor or psychologist to help cope with the diagnosis, and child-oriented 
pamphlets, storybooks, and videos.  Previous research has identified online peer support 
groups as a resource that may aid in the coping process (Burns-Pentecost, 2013).  In 
addition, a study conducted by Conlin determined that while many pediatric cardiologists 
are screening for psychosocial stressors, most do not make referrals to psychological 
services on a regular basis (2012).  However, the participants did state that they would be 
more likely to make a referral if resources were easily accessible.  Together, these 
findings suggest that establishing stronger relationships between pediatric cardiologists 






psychological support available to aid in coping with the implications of a 
cardiomyopathy associated with SADS.   
   2.5.5 Limitations and Future Research  
Common limitations of Internet-based research, such as the self-selected sample, 
unknown response rates, and inability to control who accessed the survey are all 
limitations of this study.  The individuals who chose to participate in the study were 
likely the most active members of the ion channelopathy and cardiomyopathy 
organizations and Facebook support groups.  Participants were also invited to participate 
in the survey through several diagnosis-specific Facebook groups and organizations; this 
method of obtaining participants may have biased the participant population.  The 
homogeneity of the respondents must also be noted; most individuals reported being 
Caucasian and female.  Therefore, the data collected may not be an accurate 
representation of the actions and opinions of the general population.  
 Future studies on this topic that include a more heterogeneous participant pool 
may produce less biased data.  Additional research could also investigate which aspects 
of these conversations went well and went poorly as well as obtain recommendations 
from parents on the best way to discuss children’s diagnoses with them.  This data could 
then be provided to parents of children who have recently been diagnosed with a 
cardiomyopathy associated with SADS.  Finally, researchers could obtain the perspective 
of individuals who were diagnosed as children to gain their input on what they viewed as 








2.6 Conclusions    
This study was conducted to gain a better understanding of how a child’s 
diagnosis of a heart condition associated with SADS is discussed within families.  
Participants were asked about the details of both the initial explanation and later 
conversations as well as how the risk of SCA was viewed and addressed.  The majority of 
participants thought their children either had a moderate (41%) or low (37%) risk for 
SCA and were highly concerned (53%) about this risk.  Parents reported explaining the 
risk of SCA in straightforward manner; this approach is thought to help the children and 
their parents cope with the risk.  A number of participants also related the risk of sudden 
death to why the prescribed treatment was necessary. They felt that this line of reasoning 
would encourage their children to be more compliant with the recommended medication 
regimen and lifestyle modifications.   
Information was also gathered on what aspects of these conversations parents 
found to be difficult.  Participants reported struggling with determining and enforcing 
lifestyle modifications, managing their own as well as their children’s emotional 
reactions, determining the amount and type of information to share with their children, 
and discussing the risk of the more serious symptoms. Several parents also reported 
feeling guilty for passing the condition onto their children.  Concerns regarding disease 
progression, length and quality of life, and treatment failures and complications were 
expressed as well.    
Finally, parents provided feedback on what resources were helpful and what 
resources they desired.  Healthcare professionals, the Internet, other affected people, 






SADS condition with their children.  Services and resources that were most frequently 
requested were support groups for their children, a counselor or psychologist, and child-
oriented materials.    
 Increased awareness of how families communicate about children’s diagnosis of a 
SADS condition, including the aspects parents struggle with, as well as parents’ main 
concerns and what resources are needed will allow healthcare providers to be more 
proactive about addressing these issues from the time of the initial diagnosis.  It is 
thought that this intervention will in turn facilitate more open, age appropriate discussion 
of the condition and help children and their parents more successfully cope with the 







Chapter 3. Conclusions 
This study was conducted to gain a better understanding of how a child’s diagnosis of a 
heart condition associated with SADS is discussed within families.  Participants were 
asked about the details of both the initial explanation and later conversations as well as 
how the risk of SCA was viewed and addressed.  The majority of participants thought 
their children either had a moderate (41%) or low (37%) risk for SCA and were highly 
concerned (53%) about this risk.  Parents reported explaining the risk of SCA in 
straightforward manner; this approach is thought to help the children and their parents 
cope with the risk.  A number of participants also related the risk of sudden death to why 
the prescribed treatment was necessary. They felt that this line of reasoning would 
encourage their children to be more compliant with the recommended medication 
regimen and lifestyle modifications.   
Information was also gathered on what aspects of these conversations parents 
found to be difficult.  Participants reported struggling with determining and enforcing 
lifestyle modifications, managing their own as well as their children’s emotional 
reactions, determining the amount and type of information to share with their children, 
and discussing the risk of the more serious symptoms. Several parents also reported 
feeling guilty for passing the condition onto their children.  Concerns regarding disease 
progression, length and quality of life, and treatment failures and complications were 






Finally, parents provided feedback on what resources were helpful and what 
resources they desired.  Healthcare professionals, the Internet, other affected people, 
visual aids, and personal experience were all thought to be useful for discussing the 
SADS condition with their children.  Services and resources that were most frequently 
requested were support groups for their children, a counselor or psychologist, and child-
oriented materials.    
 Increased awareness of how families communicate about children’s diagnosis of a 
SADS condition, including the aspects parents struggle with, as well as parents’ main 
concerns and what resources are needed will allow healthcare providers to be more 
proactive about addressing these issues from the time of the initial diagnosis.  It is 
thought that this intervention will in turn facilitate more open, age appropriate discussion 
of the condition and help children and their parents more successfully cope with the 
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Appendix A- Request to Host Survey  
To Whom it May Concern 
            My name is Kristin Wiley and I am a graduate student in the Genetic Counseling 
Program at the University of South Carolina School of Medicine.  For my thesis project I 
plan to gain a better understanding of how parents communicate with their children about 
a diagnosis of a cardiac condition associated with sudden arrhythmic death by surveying 
parents that have or have had a child with one of these conditions.  My survey, which is 
attached, inquires first about how parents explained their child(ren)’s diagnosis to them 
and then specifically asks questions about how they have discussed the risk of sudden 
arrhythmic arrest/death.  I realize that this is a sensitive subject for many families; 
however, I believe that by learning more about how this information is communicated 
within families, it will help guide practitioners in addressing these issues with parents in 
the future.  I would greatly appreciate your help in distributing my survey to eligible 
parents.  The more participants we have, the more we can learn about how to help 
them.  If you are willing to pass along my survey to your members please let me 









Appendix B – List of Social Media Sites Where Survey Links Were Posted 
1. Long QT Syndrome Support and Learning Community: 
https://www.facebook.com/groups/lqtssupportandlearningcommunity/ 
2. LQTS Kids & Families - for anyone affected by Long QT Syndrome: 
https://www.facebook.com/groups/193978400681765/ 
3. Cardiac Arrythmia Support Group: 
https://www.facebook.com/groups/15750922307/ 
4. Hypertrophic Cardiomyopathy....GROUP: 
https://www.facebook.com/groups/418243221551082/#_=_ 
5. SADS- Sudden Arrhythmia Death Syndrome: 
https://www.facebook.com/groups/191810694204543/ 
6. Brugada Syndrome Awareness: 
https://www.facebook.com/groups/206381569393542/ 
7. Dilated Cardiomyopathy: https://www.facebook.com/groups/8611170489/ 
8. Children's Cardiomyopathy Foundation: 
https://www.facebook.com/pages/Childrens-Cardiomyopathy-
Foundation/75335952379 








Appendix C- Invitational Letter to Participate in Survey 
Dear Potential Participant,  
 
 You are invited to take part in a graduate student research study looking into how parents 
communicate with their children about the children’s diagnoses of cardiac diseases associated 
with sudden arrhythmic death syndrome (SADS).  Participation involves completing an online 
questionnaire about your child’s diagnosis, your communication with your child(ren) about 
different aspects of the condition, and the resources you used during those conversations.  
 
 All survey responses will be kept anonymous and confidential.  The data collected during 
this study may be published or presented at medical conferences, but your responses will not be 
associated with any personally identifying information. The survey will take 15-20 minutes to 
complete.  Your participation in this research study is voluntary.  If you come across a question 
that you do not wish to answer, please skip it and continue with the survey.  You may also choose 
to not complete the survey at any time.  By completing the survey, you are consenting that you 
have read and understand this information.   
 
 As a thank you for participating in our study, you may choose to enter into a drawing to 
win a $25 gift card to the store or restaurant of your choice.  You do not have to complete the 
survey to be eligible for the drawing.  If you would like to enter into the drawing, please enter 
your contact information in the boxes provided at the bottom of the survey. Your contact 
information will only be used to send the winner his/her gift certificate and will not be associated 
with your responses.  The winner will be drawn after the study is complete. 
 
Thank you for taking the time to participate in this study. Your answers will help 
healthcare professionals such as cardiologists and genetic counselors address common obstacles 
present at the time of diagnosis and aid parents in communicating with their children about their 
condition.  If you have any questions about this research study, please contact me or my advisor 
Erin Demo at the information below.  If you have any questions about your rights as a research 




Kristin Wiley, BS                                                                Erin M. Demo, MS, CGC 
Master of Science Candidate                                        Certified Genetic Counselor  
University of South Carolina School of Medicine                               Pediatric Cardiology 
USC Genetic Counseling Program                                     Children's Healthcare of Atlanta       
Two Medical Park, Suite 208                                                                          404-694-1415 










Appendix D – Online Survey  
SECTION 1: YOUR CHILDREN’S DIAGNOSIS  
1. How many of your children have been diagnosed with a cardiac condition 
associated with SADS? 
• One  
• Two  
• Three or more  
 
2. What is the gender of your child(ren) who has/have been diagnosed  
 Child 1 Child 2 Child 3 
Female    
Male    
N/A    
 
3. What is your child(ren)’s diagnosis? 
• Long QT syndrome (LQTS) 
• Hypertrophic cardiomyopathy  
• Brugada syndrome 
• CPVT (catecholaminergic polymorphic ventricular tachycardia) 
• Arrhythmic right ventricular cardiomyopathy  (ARCV) 
• Dilated Cardiomyopathy (DCM) 
• Other (please specify) 
 
4. At what age was your child diagnosed? 
Age Child 1 Child 2 Child 3 
0-3    
4-6    
7-9    
10-12    
13-15    
16-18    
19-21    
22+    









5. Is/are your child(ren) alive or deceased  
Status Child 1 Child 2 Child 3 
Alive    




6. How old is/are your child(ren) now?  
Age Child 1 Child 2 Child 3 
0-3    
4-6    
7-9    
10-12    
13-15    
16-18    
19-21    
22+    
N/A    
 
7. Have either you or your child's other parent been diagnosed with the same SADS condition? 
If so, who has been diagnosed? 
• Yourself 
• Your child’s other parent 
• Neither parent has been diagnosed 
 
8. Who was the first person to be diagnosed in the family? 
• One of your children 
• Mother of the child(ren) 
• Father of the child(ren) 
• Grandparent of the child(ren) 
• Other (please specify)  
 
9. What was/were your child(ren)’s first presenting symptom? 
Symptom Child 1 Child 2 Child 3 
Syncope (fainting)    
Arrhythmia (abnormal 
heart rhythm) 
   
Sudden death    
Seizure    
They have not had any 
symptoms yet 
   
N/A    







10. How was/were your child(ren) diagnosed? (Please select all that apply) 
Test method Child 1 Child 2 Child 3 
Electrocardiogram 
(EKG/ECG) 
   
Echocardiogram    
Genetic Testing    
Autopsy    
Physical exam    
Exercise test    
Holter monitor (24 
hr EKG) 
   
Other (please 
specify) 
   
 
11. What symptoms has/have your child(ren) experienced to date? (Please select all 
that apply) 
Symptom Child 1 Child 2 Child 3 
Syncope (fainting)    
Arrhythmia (abnormal 
heart rhythm) 
   
Sudden death    
Seizure    
Sudden cardiac arrest    
Dizziness    
Other (please specify)    
 
12. What treatments is your child(ren) currently receiving for this condition? (Please 
select all that apply) 
Treatment Child 1 Child 2 Child 3 
Medication (like beta-
blockers) 
   
ICD: Implantable 
Cardioverter Defibrillator) 
   
Pacemaker    
Lifestyle modifications (like 
restriction from competitive 
sports) 
   
Other (please specify)    
 











SECTION 2: RISK OF SADS 
The following questions will ask you about your outlook regarding your child(ren)’s risk 
of SADS 
 
14. What do you understand to be your child(ren)’s risk of sudden cardiac arrest? 
• No risk 
• Low risk (<10%) 
• Moderate Risk 
• High Risk 
 
15. How concerned are you about your child(ren)’s risk of SADS 
• Not concerned  
• Somewhat concerned 
• Concerned 
• Very concerned 
 
 
SECTION 3: COMMUNICATION WITH YOUR CHILD  
The following questions will ask you about how you communication with your child 
about their diagnosis 
 
16. Who was involved in explaining your child’s diagnosis to him/her? (Please select 
all that apply) 
 Child 1 Child 2 Child 3 
Mother    
Father    
Other family member    
Physician    
Genetic Counselor    
Other (please specify)    
 
17. Over what period of time did the explanation of their diagnosis take place? 
Timer Period Child 1 Child 2 Child 3 
Days    
Weeks    
Months    











18. What was the primary focus of your initial explanation of his/her condition? 
(Please select all that apply) 
 Child 1 Child 2 Child 3 
Genetic aspect of the condition 
(such as the inheritance 
apptern, chance of passing it 
down to their childred) 
   
Possible symptoms 
(arrhythmia, syncope, seizures, 
sudden death, dizziness) 
   
Other family members with the 
same condition 
   
Medical Management 
(medications, ICD implant, 
lifestyle modifications (like 
limitations on physical 
activity)) 
   
How the condition specifically 
affects the heart 
   
Other (please specify)    
 
19. What topics were focused on during subsequent conversations? (Please select all 
that apply) 
 Child 1 Child 2 Child 3 
Genetic aspect of the condition 
(such as the inheritance 
apptern, chance of passing it 
down to their childred) 
   
Possible symptoms 
(arrhythmia, syncope, seizures, 
sudden death, dizziness) 
   
Other family members with the 
same condition 
   
Medical Management 
(medications, ICD implant, 
lifestyle modifications (like 
limitations on physical 
activity)) 
   
How the condition specifically 
affects the heart 
   










20. Is your child(ren)’s condition a regular topic of conversation? If so, how often is it 
discussed? 
Time Period Child 1 Child 2 Child 3 
Daily    
Weekly    
Monthly    
It is not discussed regularly    
 
21. What triggers these conversations? 
 
 
22. What were the more difficult aspects of these conversations with your child? 
Some examples include: explaining the biology, discussing lifestyle 
modifications, describing associated risks, and managing your emotions. 
 
 
SECTION 4: CONVERSATION ABOUT SADS  
23. Have you ever specifically discussed your child(ren)'s risk of sudden cardiac 




These questions will ask you about the conversations you have had with your child(ren) 
regarding their risk of SADS  
 
24. What has prompted these conversations? (Please select all that apply) 
• Diagnosis 
• Child experienced a symptom 
• Family member had an event 
• Other member of your community has an event 
• A healthcare appointment 
• Other (please specify) 
 
25. How exactly did you explain this risk of sudden cardiac arrest to your child(ren)? 
(ex: Who was involved? How did you phrase it? What did you emphasize?) 
 
 











SECTION 5: RESOURCES  
The following questions will ask you about the resources you used to help communicate 
your child(ren)’s diagnosis to them. 
 
27. What resources did you find most helpful in talking to your child(ren) about 




28. Looking back, what other guidance or resources would you have wanted to help 
talk with your child(ren) about their condition? 
 
Thank you for sharing your family's experience with a SADS condition. The following 
questions will ask about basic demographic information, such as your age and gender.  
 
SECTION 6: DEMOGRAPHICS  













31. What is the highest level of school you have completed or the highest degree you 
have received? 
• Less than high school degree 
• High school degree or equivalent (e.g. GED) 
• Some college but no degree 
• Associate degree 
• Bachelor degree 












32. What is your ethnicity? (Please select all that apply) 
• American Indian or Alaskan Native 
• Asian or Pacific Islander 
• Black or African American 
• Hispanic or Latino 
• White/Caucasian 
• Prefer not to answer 
 
33. Which of the following best describes your current relationship status? 




• In a domestic partnership or civil union 
• Single, but cohabitating with a significant other 
• Single, never married  
 
 
If you wish to enter the drawing for the $25 gift card to the store or restaurant of your 
choice, please enter your contact information below. This information will only be used 
in the drawing and will not be connected to your answers. 
 
34. Contact Information 
• Name: 
• Street Address: 
• City:  
• State:  
• Zip Code: 
• Telephone Number:  





















Appendix E – Additional Data 
  Frequency Percentage (%) 
Number of Affected 
Children in the family 
 N=114  
 One 79 69.3 
 Two 29 25.4 
 Three 6 5.3 
Parents’ Diagnosis  N=112  
 Participant is affected 54 48.2 
 Child(ren)’s other parent is affected 16 14.3 
 Neither parent is affected  42 37.5 
First Person in the 





 Child 61 53.5 
 Mother of child 26 22.8 
 Father of child 5 4.4 
 Grandparent of child 7 6.1 
 Great-grandparent of child 4 3.5 
 Aunt or uncle of child 5 4.4 
 Other  6 5.3 
 
 
  Frequency  Percentage (%) 






Child 1 Child 2 Child 3 
Vital Status         
 Alive  108 34 6 94.7 97.1 100 
 Deceased  6 1 0 5.3 2.9 0 
Method of Diagnosis         
 EKG 71 18 6 64.0 51.4 100 
 ECHO 55 14 5 48.2 40.0 83.3 
 Genetic 
Testing  
54 22 6 47.4 62.9 100 
 Autopsy 3 0 0 2.6 0 0 
 Physical 
Exam 
20 4 3 17.5 11.4 50 
 Exercise Test  30 9 4 26.3 25.7 66.7 
 Holter  38 12 5 33.3 34.3 83.3 








   Frequency  Percentage (%) 
 Child 2 Child 3 Child 2 Child 3 
Gender  N=35 N=6   
 Female 16 4 45.7 66.7 
 Male 19 2 54.3 33.3 
Age at Diagnosis  N=35  N=6   
 0-3 6 3 17.1 50.0 
 4-6 5 1 14.3 16.7 
 7-9 9 2 25.7 33.3 
 10-12 7 0 20.0 0 
 13-15 4 0 11.4 0 
 16-18 3 0 8.6 0 
 19-21 1 0 2.9 0 
 22+ 0 0 0 0 
Current Age   N=35 N=6   
 0-3 0 0 0 0 
 4-6 2 1 5.7 16.7 
 7-9 8 4 22.9 66.7 
 10-12 13 1 37.1 16.7 
 13-15 3 0 8.6 0 
 16-18 2 0 5.7 0 
 19-21 2 0 5.7 0 
 22+ 4 0 11.4 0 
 Deceased 1 0 2.9 0 
First Presenting 
Symptom  
 N=30 N=6   
 Syncope 5 0 14.3 0 
 Arrhythmia  3 2 8.6 33.3 
 Sudden Death 1 0 2.9 0 
 Seizure 0 0 0 0 
 Heart murmur 0 0 0 0 
  Shortness of breath 0 0 0 0 
 Asymptomatic 19 4 54.3 66.7 
























 Frequency  Percentage  




Child 2 Child 3  
People Involved in the 
Explanation  
     
 Mother  30 6 85.7 100.0 
 Father 17 5 48.6 83.3 
 Other Relative 2 1 5.7 16.7 
 Physician 24 6 68.6 100.0 
 Genetic Counselor 7 2 20.0 33.3 
Time Frame for the 
Explanation  
     
 Days  12 3 34.3 50.0 
 Weeks 6 0 17.1 0 
 Months  7 1 20.0 16.7 
 Years 10 2 28.6  
Primary Focus of the 
Initial Explanation  
     
 Genetics 13 2 37.1 33.3 
 Possible Symptoms 18 5 51.4 83.3 
 Other affected family 
members  
16 3 45.7 50.0 
 Medical Management 16 6 45.7 100.0 
 How the condition 
specifically affects the 
heart 




     
 Genetics 18 4 51.4 66.7 
 Possible Symptoms 21 6 60.0 100.0 
 Other affected family 
members  
23 6 65.7 100.0 
 Medical Management 17 4 48.6 66.7 
 How the condition 
specifically affects the 
heart 
15 6 42.9 100.0 
Frequency of 
discussion  
     
 Daily  6 0 17.1 0 
 Weekly 12 4 34.3  
 Monthly 5 1 14.3 16.7 
 Not discussed 
regularly 
10 1 28.6 16.7 
 
